{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:28:06Z","timestamp":1747207686261},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":16745,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1970,3]]},"abstract":"<jats:p>Cephaloglycin, 0.5 Gm. orally daily for 10 days (Regimen 1); K phenoxymethyl penicillin, 0.5 Gm. orally daily for 10 days (Regimen 2); K phenoxymethyl penicillin, 1.0 Gm. orally daily for 7 days (Regimen 3); and benzathine penicillin G, 0.5 Gm. once intramuscularly (Regimen 4) were compared in 180 patients with group A streptococcal pharyngitis. The regimens were assigned randomly. Bacterial failure rates for primary treatments were: Regimen 1, 10 per cent; 2, 17 per cent; 3, 28 per cent; and 4, 9 per cent. Bacterial failure rates for retreatments were: Regimen 1, 29 per cent; 2, 67 per cent; and 4, 75 per cent. Possible side efJects of Regimen 1 were generalized maculopapular rashes in 11, other rashes in 2, and mild diarrheas in one third. The minimal inhibitory concentrations of cephaloglycin and penicillin G for 98 group A streptococci averaged 0.2 P,g per milliliter and 0.01 P,g per milliliter, respectively. Cephaloglycin concentrations showed a mean average of 0.8 P,g per milliliter in 30 sera obtained 1 to 2 hours after ingestion of 125 mg. doses during therapy.<\/jats:p>","DOI":"10.1002\/cpt1970112205","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:08:51Z","timestamp":1451956131000},"page":"205-213","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of cephaloglycin and penicillin in streptococcal pharyngitis"],"prefix":"10.1111","volume":"11","author":[{"given":"Maxwell","family":"Stillerman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1970112205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1970112205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1970112205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:33:34Z","timestamp":1699364014000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1970112205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1970,3]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1970,3]]}},"alternative-id":["10.1002\/cpt1970112205"],"URL":"https:\/\/doi.org\/10.1002\/cpt1970112205","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1970,3]]}}}